Telix Pharmaceuticals shares (ASX: TLX) jumped 7% to $14.60 into the weekend, leading a broader rally in medical technology stocks on the ASX 200, after the US Food and Drug Administration formally accepted the company’s resubmitted New Drug Application for its glioma imaging agent.
The Melbourne-based radiopharmaceutical company’s shares reached their highest close of 2026, extending year-to-date gains to 28% and marking a 65% surge since mid-February. The stock led a strong session for the healthcare sector, including peers 4DMedical (up 7.47%) and Mesoblast (up 5.17%). Despite the recent momentum, Telix shares remain approximately 45% below their levels from twelve months ago, reflecting the substantial volatility that has characterised the stock’s journey through regulatory setbacks and short-seller pressure during 2025.
The rally came as markets digested news that the FDA has set a Prescription Drug User Fee Act goal date of 11 September 2026 for TLX101-Px, marketed as Pixclara. This regulatory milestone provides investors with a clear timeline for a potential approval decision, offering the kind of tangible catalyst that event-driven buyers typically favour in the biotechnology sector.
Regulatory Breakthrough and Solid Revenue Boost Sentiment
The FDA’s acceptance of the NDA represents a critical de-risking event for Telix’s glioma imaging franchise. TLX101-Px is an 18F-FET PET imaging agent designed to help clinicians differentiate between recurrent or progressive glioma and treatment-related changes in the brain, a persistent diagnostic challenge in neuro-oncology that affects both adult and paediatric patients.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The product has been granted both Orphan Drug and Fast Track designations by the FDA, regulatory classifications that signal the agency’s recognition of high unmet medical need and typically facilitate more frequent dialogue during the review process. Orphan status also provides Telix with potential pricing flexibility and market exclusivity advantages should approval be granted.
Importantly, 18F-FET neuro-imaging is already recommended in international clinical guidelines, including those published by the National Comprehensive Cancer Network, for glioma assessment. This existing guideline support increases the likelihood of faster clinical adoption in the US market if Pixclara secures regulatory clearance.
Telix’s first quarter 2026 trading update, released days before the FDA announcement, showed unaudited group revenue of US$230 million, representing 11% sequential growth from the prior quarter. The company’s commercial backbone remains its prostate cancer imaging agent Illuccix, which continues to generate the cash flows funding Telix’s ambitious pipeline expansion.
The Q1 update also highlighted geographic diversification efforts, including acceptance by China’s National Medical Products Administration of an NDA for TLX591-Px, another prostate cancer imaging product. This China opportunity represents an additional medium-term growth vector independent of the Pixclara opportunity in the United States.
Management has committed to reinvesting aggressively in research and development, with R&D expenditure expected to reach between US$200 million and US$240 million across 2026. This heavy reinvestment load reflects the company’s ambition to evolve from a single-product imaging business into a diversified radiopharmaceutical platform spanning both diagnostics and therapeutics.
Theranostic Platform Ambitions
Beyond the imaging agent, Telix is advancing TLX101-Tx, a therapeutic radiopharmaceutical targeting the same LAT1 biological pathway, through the pivotal Phase 3 IPAX-BrIGHT trial in glioblastoma patients. The therapy has secured orphan drug designation in both the US and European Union and aims to address one of oncology’s most devastating and treatment-resistant diseases.
Earlier-phase trials demonstrated evidence of tumour responses and disease stabilisation, though glioblastoma Phase 3 programs historically carry substantial execution risk. The parallel development of TLX101-Px as a diagnostic companion and TLX101-Tx as a therapy fits the increasingly popular theranostic model in nuclear medicine, where the same biological target is used for both imaging and treatment.
Success with Pixclara could serve to validate the LAT1 platform and potentially accelerate regulatory and commercial pathways for the therapeutic candidate, a dynamic that underpins the longer-term bull case for Telix as a franchise rather than a single-asset story.
What Lay Ahead
Markets will now focus intently on the pathway to the September 2026 PDUFA date, watching for any FDA information requests, potential advisory committee scheduling, or updates on US reimbursement positioning. Any indication of label discussions or additional data requirements would be scrutinised for signals about approval probability.
Beyond Pixclara, execution against fiscal 2026 guidance, which excludes any contribution from the brain imaging agent, will be critical to maintaining confidence in the core Illuccix business and demonstrating that Telix can sustain growth while funding its ambitious pipeline. Updates on the IPAX-BrIGHT trial and progress toward resubmission of other delayed programs will provide secondary catalysts through the remainder of the year.
The sharp rebound from February lows suggests markets are beginning to repair the regulatory-risk discount that weighed on the stock through 2025, though scepticism remains in current pricing, leaving plenty of room for further moves if the fundamentals support.
